ImmuPharma PLC (AIM: IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has received advance assurance from H M Revenue and Customs that it would qualify for Enterprise Investment Scheme (EIS) status. EIS offers a range of tax reliefs to investors who invest in qualifying companies.  These tax reliefs…

Deal provides powerful validation for Lupuzor™ ImmuPharma PLC (AIM: IMM) (“ImmuPharma”) and Simbec-Orion Group Limited (“Simbec-Orion”) announce that they have today entered into a Collaboration Agreement for the execution of ImmuPharma’s Pivotal Phase III clinical study of Lupuzor™. Lupuzor™ (also known as Rigerimod, IPP-201101 and P140), is ImmuPharma’s lead compound for the treatment of Lupus,…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is proud to announce that the French region of Aquitaine (around Bordeaux) has awarded ImmuPharma’s subsidiary Ureka a non-refundable grant of approx. €400,000 EUR to develop Ureka’s Urelix technology. The Urelix technology is a way to mimic natural peptides having a…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has conditionally, raised approximately £3.4 million. This is principally from ImmuPharma’s long standing shareholder Aviva Investors through a placing of 6,340,000 new ordinary shares of 10p each in the Company, at a price of 53 pence per share,…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2014. KEY HIGHLIGHTS • LupuzorTM – Announced separately today – Phase III activities of lead compound Lupuzor™ will soon commence: Following advanced discussions and after completing detailed due diligence…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is delighted to announce that Phase III activities of its lead compound Lupuzor™ will soon commence. Following advanced discussions and after completing detailed due diligence with a potential partner, ImmuPharma has started the preparatory steps for Lupuzor’s™ pivotal phase III clinical…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed. A summary of proxy votes is shown in the table below. Please also refer to the ‘Notice of Meeting’ in the Report & Accounts –…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is delighted to provide further details on its activities in the Bordeaux region of France, working closely with one of its key collaborators at the CNRS*, ImmuPharma’s longstanding research partner, accessing novel drug research in the area of peptides. One key…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is delighted to announce that the US Patent and Trademark Office has granted a notice of allowance for an “optically pure” version of ImmuPharma’s Nucant family. A similar grant has been obtained from the EU, Japanese and Australian patent offices. The…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its preliminary audited results for the year ended 31 December 2013. Key Highlights: LupuzorTM Discussions continue with potential partners in parallel to discussions with Contract Research Organisations and alternative financing organisations for LupuzorTM’s pivotal Phase III programme…

ImmuPharma PLC (AIM:IMM) (the “Company”)  the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2013 will be posted to shareholders today. The Annual Report is available, in electronic form, for download on the Company’s website www.immupharma.co.uk. The Company’s Annual General Meeting will be held…

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, provides a summary of the presentation given by Dr. Slyviane Muller at the European Lupus Conference which recently took place in Athens, Greece. The “European Lupus Meeting” is a major forum for all people interested in the disease: with approximately…

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce that Dr. Sylviane Muller was recently invited by the Immunology Frontier Research Center of Osaka University, an internationally renowned research center in the field of immunology, to hold a seminar on the approach of Lupuzor for…

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to confirm that it is sponsoring the forthcoming European Lupus Conference which takes place in Athens, Greece from April 23 – 26, 2014. The “European Lupus Meetings” is a major forum for all people interested in the disease:…

ImmuPharma plc (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist drug discovery and development company is pleased to provide an update on its lead cancer programme IPP-204106. As announced in September last year the Company commenced dosing in cancer patients with the next generation of the “polyplexed Nucant” (See notes to editors). Three…

ImmuPharma plc (LSE:IMM) (“ImmuPharma” or the “Company” or the “Group”), the specialist drug discovery and development company, is delighted to announce that following its discussions with the FDA (the US Food & Drug Administration), it has been granted an updated SPA (Special Protocol Assessment) for Lupuzor. Under the new SPA, the necessary number of patients…

ImmuPharma plc (LSE:IMM) (“ImmuPharma” or the “Company” or the “Group”), the specialist drug discovery and development company, is delighted to announce that it has appointed some of the world’s most eminent physicians to provide scientific advice and support for Lupuzor’s pivotal phase III programme. The Five Scientific Adisory Board members are: Dr. Daniel J. Wallace,…

Facility Underwritten by Henderson Global’s Subsidary Darwin Strategic ImmuPharma plc (LSE:IMM) (“ImmuPharma” or the “Company” or the “Group”), the specialist drug discovery and development company, is pleased to announce that it has secured a £50 million, five year Equity Financing Facility (“EFF”) with Darwin Strategic Limited (“Darwin”), a majority owned subsidiary of Henderson Global Investors’…

Immupharma’s (LON:IMM) new lupus treatment Lupuzor has the potential to offer substantial benefits to patients compared with current market leader Benlysta, new research has suggested. A survey of US and European rheumatologists carried out by Decision Research indicated emerging therapies such as Lupuzor had the potential to improve on IV belimumab (Human Genome Sciences/GlaxoSmithKline’s Benlysta)…

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announces that it has been informed by Baader Bank AG that its shares are now being traded on the third segment  of the Stuttgart Stock Exchange. Baader Bank AG has experience and expertise for trading in German…

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce that its key scientific collaboration partner and the inventor of ImmuPharma’s lead compound, LupuzorTM has issued a press release confirming the effectiveness of the LupuzorTM peptide P140. LupuzorTM is ImmuPharma’s lead compound and potential blockbuster drug…